Targeted cancer therapy remains a major challenge in the eradication of tumors. Drug delivery systems using nanoparticles offer a novel approach to specifically delivering drugs to cancer cells while sparing normal cells [1] [2] [3] [4] . Glioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor representing 32% of all brain tumor cases in adults, and 81% of malignant tumors [5]. With the current treatment approach including surgical resection and radiotherapy with concomitant chemotherapy, GBM still has a grim prognosis with a median overall survival of 15-18 months [6] . A major challenge in the treatment of GBM is to deliver therapeutics across the blood-brain barrier (BBB), a network of specialized brain endothelial cells with intercapillary distances of approximately 40 μm that tightly regulate ionic composition, prevent macromolecules and unwanted cells from entering the brain to protect the CNS from neurotoxins [7, 8] . Moreover, it is believed that antitumor drugs cannot reach glioblastoma stem-like cells because they hide in a hypoxic microenvironment near BBB vasculature [9] . The use of targeted drug delivery with relatively small magnetically directed nanoparticles (<40 nm) has been demonstrated as an efficient way to cross BBB, target cancerous cells and permit an on-demand release of antitumor drugs [10] .
Targeted cancer therapy remains a major challenge in the eradication of tumors. Drug delivery systems using nanoparticles offer a novel approach to specifically delivering drugs to cancer cells while sparing normal cells [1] [2] [3] [4] . Glioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor representing 32% of all brain tumor cases in adults, and 81% of malignant tumors [5] . With the current treatment approach including surgical resection and radiotherapy with concomitant chemotherapy, GBM still has a grim prognosis with a median overall survival of 15-18 months [6] . A major challenge in the treatment of GBM is to deliver therapeutics across the blood-brain barrier (BBB), a network of specialized brain endothelial cells with intercapillary distances of approximately 40 μm that tightly regulate ionic composition, prevent macromolecules and unwanted cells from entering the brain to protect the CNS from neurotoxins [7, 8] . Moreover, it is believed that antitumor drugs cannot reach glioblastoma stem-like cells because they hide in a hypoxic microenvironment near BBB vasculature [9] . The use of targeted drug delivery with relatively small magnetically directed nanoparticles (<40 nm) has been demonstrated as an efficient way to cross BBB, target cancerous cells and permit an on-demand release of antitumor drugs [10] .
Recently developed magnetoelectric nanoparticles (MENs) are a novel class of nanoparticles to enable targeted drug delivery across BBB and externally controlled release deep in the brain [11] [12] [13] [14] . Due to the multiferroic physics of MENs, these nanoparticles offer properties that cannot be achieved by any other type of nanoparticles, such as traditional ferromagnetic nonsuperparamagnetic and superparamagnetic iron oxide nanoparticles and other magnetic or nonmagnetic metallic and polymer nanostructures. Like the traditional magnetic nanoparticles, MENs have a nonzero saturation magnetization and therefore can be navigated throughout the body by the application of magnetic field gradients, and localized using conventional image-guided magnetic approaches such as MRI and magnetic particle imaging. In addition, unlike the traditional nanoparticles, MENs display a quantum mechanically induced nonzero magnetoelectric (ME) effect; the ME effect allows a reciprocal control including a control of the nanoparticles' electric dipole moments by a local magnetic field and a control of their magnetic moments by a local electric field, respectively. Because MENs' electric dipole moment also defines drug carrier properties, mainly; the strength of the bond between the nanoparticle and the loaded drug, and the local electric field in MENs' proximity, drug delivery and release also can be controlled via application of special sequences of d.c. and a.c. magnetic fields. Previously, through in vitro and in vivo experiments, the following properties have been demonstrated. First, MENs were shown to deliver antiretroviral therapy across BBB to eradicate HIV-1 virus hidden deep in the brain [15] . Second, drug-loaded MENs demonstrated a relatively high specificity to cancer cells by penetrating the cancer cell membrane, while sparing the surrounding healthy cells, and then releasing the drug intracellularly via application of d.c. and a.c. magnetic fields, respectively. The hypothesis of high-specificity targeted delivery has been verified through in vitro and in vivo studies on ovarian cancer in mice bearing SKOV-3 human ovarian carcinoma xenografts [11, 12] .
Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the synthesis and release of GH in the pituitary gland [16] . GHRH and its mRNA are expressed in many human cancers, suggesting that it may act as a tumor growth factor [17, 18] . GHRH is specifically expressed in glioblastomas. GHRH antagonists have been studied as a treatment for this tumor type [19, 20] . GHRH antagonists are a class of antitumorigenic peptides that block the release of insulin-like growth factor I (IGF-1), a tumor factor growth factor that plays an important role in the mechanism of malignant transformation, metastasis and tumorigenesis of various cancers, including GBM [21] [22] [23] . GHRH antagonists exert direct effects on GHRH receptors on tumor cells by reducing IGF-I and IGF-II in tumor tissue. GHRH antagonists also directly compete with autocrine/paracrine secretion of GHRH that is known to enhance cancer cell proliferation [24] . However, major challenges in treatment with GHRH antagonist include prolonging drug half-life and delivering drug across the BBB for localized drug release specifically to glioblastoma cells [25, 26] . It is well established that the MIA class of GHRH antagonists exhibits high binding affinities to GHRH receptors and display anticancer properties [21, 22, [25] [26] [27] [28] [29] [30] [31] [32] . MIA690 is a synthetic peptide that belongs to the class of MIA GHRH antagonists and has been recently developed as a promising treatment for glioblastomas [32, 33] .
Combining the effectiveness of GHRH antagonists and the MEN-based externally controlled targeted drug delivery may provide a promising therapy in treating GBM. However, open questions include whether MIA690 peptides can bind to MENs with sufficient affinity to penetrate human glioblastoma cell membranes and then be released on-demand from MENs into the intracellular space following a sequence of externally applied d.c. and a.c. magnetic fields according to the MENs' ME physics. Furthermore, it is important to demonstrate that MENs can avoid uptake in nonmalignant cells of the brain vasculature when exposed to equivalent d.c. field gradients and thus minimize any collateral damage.
Therefore, the primary aims of this paper are to present an in vitro study in which MIA690 is efficiently bound to MENs as a drug delivery carrier, MIA690-loaded MENs can deliver GHRH to human glioblastoma cell membranes via application of a d.c. magnetic field and release of MIA690 through the application of an a.c. magnetic field without thermal damage. We demonstrate that the unique properties of MENs allow it to specifically target human glioblastoma cells, providing a potential nanotechnology solution to overcome challenges in the treatment of GBM.
Materials & methods

Materials
MENs were synthesized using chemicals purchased from Sigma-Aldrich (MO, USA). Cellular experiments in vitro utilized the human glioblastoma cell line (U-87MG) and human brain microvascular endothelial cells (HBMECs) obtained from the commercial provider American Tissue Culture Collection (VA, USA). Modified Eagle's medium (MEM), Dulbecco's Modified Eagle's medium (DMEM), fetal bovine serum (FBS) from Gibco (NY, USA) and penicillin-streptomycin (penstrep) were obtained from Science-Cell, Inc. (CA, USA). For fluorescence experiments, fluorescein isothiocyanate (FITC) amine reactive dye and 4 ,6-Diamidino-2-Phenylindole (DAPI) were purchased from Thermo Fisher Scientific (MA, USA). All reagents met or exceeded ACS standards for procedures requiring stringent quality specifications.
Synthesis & characterization of magnetoelectric nanoparticles
MENs were synthesized in our laboratory by conventional methods [34] . In the first step, CoFe 2 O 4 core particles were prepared by the standard hydrothermal method. Thus, 0.58 g of Co(NO 3 ) 2 •6H 2 O and 0.16 g of Fe(NO 3 ) 3 •9H 2 O were dissolved in 150 ml of aqueous solution. An aqueous mixture of polyvinylpyrrolidone (0.2 g) and sodium borohydride (0.9 g) was then added and stirred at 70
• C for 12 h. The precursor solution of BaTiO 3 was prepared by mixing 174 mg of BaCo 3 and 5 g citric acid with 240 μl titanium isopropoxide in ethanolic solution. CoFe 2 O 4 cores were added to the BaTiO 3 precursor solution and sonicated until fully dispersed (∼2 h). The mixture was heated at 90
• C with continuous stirring overnight to form a milky opaque gel. The gel was placed in the KSL-1100x high-temperature muffle furnace from MTI Corporation (CA, USA) to calcine at 600
• C for 5 h with controlled ramping temperatures to obtain core-shell of MENs of approximately 30 nm diameter. Size distribution of MENs was confirmed by atomic force microscope imaging to assess grain height using the Bruker Nanoscope IIIa Multimode (MA, USA) and TEM imaging using the FEI Talos F200X instrument (OR, USA).
Conjugation of growth hormone-releasing hormone antagonist peptide MIA690 to magnetoelectric nanoparticles Five grams of 30 nm CoFe 2 O 4 -BaTiO 3 core-shell MENs were resuspended in 1 ml sterile phosphate-buffered saline (PBS, pH 7.4) and sonicated for 1 min. To improve the biocompatibility of MENs, 0.1 ml of glycerol monooleate (GMO) was mixed with the MEN core-shell and rotated for 1 h. GMO-MENs were washed thrice with PBS, then N-(3-Dimethylaminopropyl)-N -ethyl-carbodiimide hydrochloride (EDC) at 1 mg/ml concentration was added to the solution and incubated for 1 h by slow mechanical stirring. The GHRH antagonist, synthesized by R-Z Cai and AV Schally using solid-phase methods was conjugated to the functionalized GMO-MENs to produce a stock solution of MIA690-GMO-MENs that could be mixed with cell culture media to a final peptide concentration of 1 μM MIA690. The treatment with GHRH antagonists at the concentration of 1 μM has previously reduced cell viability and generated antitumor effects in GBM cell culture [26] . To determine the binding efficacy of MIA690 to GMO-MENs, stock solution was centrifuged at 4000 r.p.m. to separate unbound peptide from the pellet. The supernatant was resuspended in PBS and absorbance was measured spectrophotometrically and concentrations were plotted against a calibration curve of known MIA690 concentration.
Cell culture U-87MG cells were grown in T-25 flasks seeded with 0.5 × 10 6 cells/flask and cultured with MEM media supplemented with 5% FBS and 1% penstrep. HBMECs were grown in DMEM media supplemented with 10% FBS and 1% penstrep. Cell cultures were incubated at 37
• C with 5.0% CO 2 in a humidified atmosphere. Media was replaced every 2-3 days until cells reached confluency. Confluent cells were detached with 0.25% trypsin/EDTA solution and reseeded.
Drug uptake experiments were performed at 80% confluency, and data were collected at 24 and 48 h posttreatment with MIA690-loaded MENs or MIA690 alone. Samples were read in duplicate and triplicate when necessary to obtain acceptable % CV values.
In vitro treatment Cells were treated with MIA690 alone or MIA690-GMO-MENs in fresh media at a concentration of 1 μM of MIA690. Equivalent volumes of the vehicle solutions ('naked' GMO-MENs or PBS) were added to the media as controls. Each treatment group (MIA690, MIA690-GMO-MENs, GMO-MENs, PBS) was exposed to several magnetic field conditions to test the effect of a d.c. magnetic field gradient (reported in Oe) to induce penetration into U-87MG cells. Subsequently, selected treatment groups were exposed to an a.c. magnetic field (reported in Hz) to examine the on-demand release of MIA690 from the nanoparticle. The duration of exposure to a magnetic field was controlled to determine the optimal exposure time that would improve MIA690 uptake. We chose a combination of treatment groups based on prior MEN data [11, 12, 15] ; U-87MG cells treated with MIA-GMOMENs were exposed to the following magnetic fields in sequence: no field, 0 Oe + 0 Hz; 2 h 100 Oe + 0 Hz; 2 h 100 Oe + 50 Hz 30 min; 2 h 100 Oe + 50 Hz 2 h; 12 h 100 Oe + 50 Hz 30 min; 12 h 100 Oe + 50 Hz 2 h (Supplementary Figure 1) .
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Intracellular release of growth hormone-releasing hormone antagonist MIA690 from magnetoelectric nanoparticles in glioblastoma multiforme To determine the amount of intracellular uptake and release of MIA690, the amount of free drug in the cell lysate was quantified spectrophometrically. It is accepted that cell lysate components represent the intracellular content of cells [35] . Following the treatment and exposure to magnetic fields, U-87MG cells were allowed to incubate further for 24 or 48 h. Then media was discarded and cells were washed with PBS and detached with 0.25% trypsin/EDTA solution. Cells were collected in a conical tube, pelleted by centrifugation and washed thrice with ice-cold PBS. Cells were resuspended in 1 ml DMSO and sonicated briefly to induce cell lysis. After 1 h of incubation at 37
• C, the solution was centrifuged at 10,000 r.p.m. for 5 min to pellet cellular debris and MENs. The supernatant containing the cell lysate was collected to measure the intracellular concentration of MIA690.
Quantification of MIA690 uptake in cell lysate
An aliquot (20 μl) of cell lysate from each treatment group was diluted in buffer and measured spectrophometrically on scan mode to capture peak signatures of the peptide. A standard curve was generated by resuspending known concentrations of MIA690 and creating serial dilutions. Peak absorbance of MIA690 was captured at the maximum wavelength of 220 nm. MIA690 uptake was normalized to the protein content of cells lysate, which is representative of the number of cells in culture. Protein content was determined immediately after collection to avoid protein degradation with the Bradford method using Bio-Rad Protein Assay Kit at an absorbance of 595 nm according to Bio-Rad protocol (CA, USA). Final results were reported as % MIA690 per microgram protein. Spectrophometric measurements were performed by Cary 100 UV-Vis spectrophotometer (CA, USA).
Imaging intracellular uptake & specificity of magnetoelectric nanoparticles in U-87MG cells
Cell lysate from each treatment group 24 h after treatment was collected for imaging with electron-dispersive spectroscopy (EDS) mode of scanning electron microscopy (SEM). EDS-SEM detects signature traces of Ba and Ti that are unique to MENs' outer shell. The presence of Ba and Ti in cell lysate indicates efficient nanoelectroporation of U-87MG cells. One drop of lysate (∼10 μl) diluted in TE buffer was dried on a precleaned Si wafer and placed on copper tape mounting for imaging with a JEOL JIB-4500 multibeam system (focussed ion beam/SEM; MA, USA). The Thermo Scientific Noran system 7 performed EDS analysis. Intracellular uptake of GMO-MENs was observed by comparing the density of Ba and Ti signal in each image. ICP-MS confirmed the presence of Ba and Ti in the cell lysate.
For specificity data of MENs, malignant U-87MG cells and nonmalignant HBMECs were cultured as previously described and treated with FITC-loaded MENs (FITC MENs) and DAPI for nuclear staining. U-87MG cells and HBMECs were exposed to a magnetic field gradient of 100 Oe and intracellular uptake of MENs was quantified using a confocal fluorescent microscope Olympus Fluoview FS1200 (PA, USA).
Cell viability & magnetic nanoparticle hyperthermic effect
In vitro cell viability of U-87MG cells after treatment with MIA690 or MIA690-GMO-MENs and magnetic field exposure was determined using the trypan blue protocol [36] . Experimental conditions were identical to those of the treatment groups described previously. Reported results are relative to the control group treated with a PBS vehicle solution.
The magnetic fields used to induce nanoelectroporation may cause heat dissipation known to produce hyperthermic effects resulting in cell death. Infrared (IR) imaging captured by the FlIR-i3 camera (OR, USA) measured heat dissipation at each stage of treatment to ensure that cell culture temperatures remained within normal ranges. Temperatures were captured at the maximal magnetic field exposures.
Statistical analysis
Results are presented as mean ± standard deviation or percentages. Student's t-test and one-way ANOVA with post hoc analyses were conducted to assess significant differences between treatment groups. Linear regression models were used to assess relationships between variables of interest. Statistical analysis was performed using IBM SPSS software (IL, USA). P-values < 0.05 were considered statistically significant. 
Results
Characterization of magnetoelectric nanoparticles
Atomic force microscope and TEM-EDS images of 30-nm MENs are shown in Figure 1A & B, respectively. X-ray diffraction confirmed the tetragonal crystal structure of BaTiO 3 shell (space group P4 mm, a = 3.9940Å, c = 4.0380Å) and the cubic structure of CoFe 2 O 4 cores (data not shown). Vibrating sample magnetometry results showed that the magnetic moment/coercivity of the CoFe 2 O 4 core was approximately 1 emu/g and that of the core-shell particles was 40 emu/g. Growth hormone-releasing hormone antagonist MIA690-loaded magnetoelectric nanoparticles To ensure adequate biocompatibility, MENs were coated with GMO before conjugation with MIA690, as described in detail in 'Materials & methods' section. Using GMO ensured that the fields necessary for inducing local electroporation of the cell membrane and consequent release of the peptide into the cell were within adequate ranges of magnitudes (∼<100 Oe) and frequencies (∼<1000 Hz). The GMO functionalization approach has been previously described [37] . The effectiveness of the conjugation procedure was tested by creating a standard calibration curve from MIA690 stock solution and measuring the absorbance maxima of the unbound MIA690. The retained percentage of MIA690-GMO-MENs, P, was calculated using the following expression: Results indicated that the functionalized GMO-MENs carrier could retain 72.7% of MIA690 (Figure 2 ). with MIA690 and normalized by the Bradford method. It should be noted that MIA690 needs to be released from the MENs to be bioactive and thus act on cell receptors. The time of release is dependent on the durations of the d.c. and a.c. field application, as shown in Figure 3 . The increase in the incubation time with MENs complicates the estimation of membrane-bound GHRH because a fraction of MENs (with unreleased GHRH) may enter the cell (at 12 h). Therefore, we have reported the measured GHRH levels in the cell lysate. The Bradford method to detect proteins was used to normalize drug content in lysate relative to the number of cells in the sample. The Bradford method is reported to detect peptides >3000 kDa, which is beyond the limit of MIA690 (MW = 3934 Da). To ensure the peptide MIA690 did not significantly contribute to absorbances obtained by the Bradford method, we measured the maximum concentration of the peptide treatment (1 μM MIA690) using the Bradford method. Results indicated absorbances of MIA690 were negligible compared with the average protein content of cells indicating that MIA690 is of interest but does not contribute to protein values (Supplementary Figure 2) . Results from intracellular measurements suggest that MIA690 uptake increased significantly only in cells treated with MIA690-loaded MENs and exposed to 100 Oe for 12 h in lysate collected 24 h post-treatment. Drug uptake increased by a factor of 6.9 for MIA690 carried by field-controlled MENs exposed to an extended d.c. field compared with the drug administered alone, and this factor increased to 11 with on-demand release using an a.c. magnetic field for 2 h ( Figure 3A) . Notably, cells exposed to brief d.c. fields (∼2 h) did not significantly increase intracellular release of MIA690 regardless of a.c. field exposure.
In cell lysate measurements 48 h post-treatment, uptake of MIA690 is increased by a factor of at least 4.6 in cells treated with MIA690-loaded MENs and exposed to 100 Oe for 12 h with and without the application of an a.c. field ( Figure 3B) ; however, these results did not reach statistical significance.
future science group www.futuremedicine.com U-87MG cell viability decreases with MIA690-loaded magnetoelectric nanoparticle delivery A key mechanism of action of the GHRH antagonist MIA690 is to inhibit cancer cell proliferation [32] . We investigated the effect on cell inhibition when MIA690 was delivered to U-87MG cells via field-controlled MENs as drug delivery vehicles. U-87MG cells were treated with MIA690 drug only, and MIA690 bound to GMO-MENs as a drug delivery vehicle. Vehicle controls included PBS only and GMO-MENs only under a magnetic field of 100 Oe. Viability was measured by taking an aliquot from the sample of cells and staining it with trypan blue, a dye that will distinguish between viable cells and dead cells in triplicate. Results show a decrease in cell viability at 24 h post-treatment when MIA690 was delivered through GMO-MENs and exposed to a field of 100 Oe d.c. for 12 h and 50 Hz for 2 h, however the results were not statistically significant compared with traditional treatment of MIA690 alone (-7.8%, p = 0.285). Cell death was enhanced at 48 h in cells treated with MIA690 bound to GMO-MENs and exposed to 100 Oe for 12 h then 50 Hz for 2 h compared with MIA690 treatment alone (-18.3%, p = 0.03) ( Figure 4A ). The relationship between % intracellular MIA690 levels and % cell inhibition is plotted in Figure 4B . There is a significant relationship between intracellular MIA690 levels and % cell inhibition, indicating that increased intracellular MIA690 is significantly associated with cell growth inhibition (R 2 = 0.43, p = 0.001).
The effect of a low a.c. magnetic field on heat dissipation & cell viability As expected, relatively low magnetic fields used to couple with MENs did not produce significant heating across treatment groups. The a.c. frequency used in this study is in the near-d.c. range and thus barely induces hysteresistriggered thermal dissipation. FlIR-i3 IR imaging measured heat dissipation at each stage of field exposure to magnetic field. There were no significant differences between flask temperatures of control and GMO-MENtreated flasks, regardless of the length of time or magentic field exposure (d.c. or a.c.). Cell viability did not differ significantly between GMO-MEN-treated cells with or without exposure to a.c. magnetic fields ( Figure 5 ).
Magnetoelectric nanoparticles specifically penetrate U-87MG cells
The intracellular uptake of MENs was imaged across treatment groups using EDS-SEM. The EDS-SEM provides an atomic-level elemental composition of the material and identifies atomic signatures of GMO-MENs. Because MENs are composed of a CoFe 2 O 4 core with a BaTiO 3 shell, the atomic signatures of Ba and Ti indicate the presence of MENs in the cell lysate. The samples showing the highest traces of Ba and Ti were those exposed to 100 Oe for 12 h compared with controls, indicating that MENs loaded with MIA690 effectively penetrate U-87MG cells with the application of a d.c. magnetic field ( Figure 6A ). ICP-MS was performed to quantify amounts of Ba and Ti in the cell lysate. Results showed that following d.c. treatment for 12 h, the average Ba concentration was 18.7 ± 2.7 μg/l and Ti concentration was 98.6 ± 2.5 μg/l, confirming the presence of MENs in cell lysate (data not shown).
Specificity of MENs to target cancer cells was investigated by treating healthy cells (HBMECs) and cancer cells (U-87MGs) with fluorescently labeled MENs. FITC-loaded MENs were redispersed in cell media and exposed to a d.c. magnetic field (∼100 Oe) hypothesized to produce electroporation in cancer cells while sparing healthy cells. Results of confocal fluorescent images indicate that FITC-MENs are highly localized in the cytoplasm of the malignant U-87MG cells and no definite association is found with the nonmalignant HMBECs ( Figure 6B ).
Discussion
Current treatment modalities for malignant glioblastomas including surgery, radiotherapy, chemotherapy or their combinations are being applied with limited success [38] [39] [40] . GHRH antagonists are being developed to improve the outcome of chemotherapy and the survival of brain cancer patients and improve chemotherapy outcomes [16, 21, 41] . The beneficial effects of GHRH antagonist in experimental treatment models include suppression of the pituitaryhepatic IGF axis, and direct inhibition of the autocrine/paracrine activity of GHRH. However, delivery of GHRH antagonists to target sites in the brain is limited by their short half-life in circulation and relatively inefficient delivery to glioblastoma. Therefore, an approach for tightly binding GHRH antagonists to a carrier particle to avoid degradation, directing the drug-loaded conjugate across the BBB and controlling the release of the drug may provide improved treatment outcomes.
The use of MENs as drug delivery vehicles for cancer therapies is being studied both in vitro and in vivo [12, 37] . Previously, we have shown that MENs as drug carriers can be loaded with a GHRH antagonist, administrated intravenously and then navigated through BBB via application of a d.c. magnetic field gradient. In general, MRI or magnetic particle imaging can be used as an imaging modality to provide an image guided delivery of MENs directly to tumor sites using d.c. magnetic field gradient. Recently, it has been shown that MENs can be localized to tumor sites due to a physical mechanism which acts independently of the enhanced permeability and retention effect [42] . According to this mechanism, drug-loaded and charged MENs are attracted to the tumor cells due to their more conductive membrane surface and the resulting stronger Coulomb force compared with that for the normal cells. When in close proximity to the tumor cell membrane, MENs induce local electroporation of the cell membrane, the effect known as the nanoelectroporation, which further pulls the nanoparticles inside the cells. The specificity exists because the nanoelectroporation threshold field for the malignant cells is significantly lower than that for the surrounding nonmalignant cells [43, 44] . Upon entering into the cytosol, an on-demand release of the peptide into the intracellular microenvironment is achieved by application of an a.c. magnetic field. As described in detail in previous publications, the physical mechanism of the release relies on the strong a.c. field dependence of the bond affinity between the nanoparticle and the drug due to the ME effect [15] .
The present data support the concept that MENs can effectively bind to the GHRH antagonist MIA690 at physiological pH and can deliver MIA690 more efficiently to malignant glioblastoma cells than the free drug alone in vitro. Furthermore, the data confirm that MENs exposed to a controlled magnetic field show specificity to malignant glioblastoma cells while sparing nonmalignant cells.
Conjugation of MIA690 to GMO-MENs using an EDC-linker resulted in 72% of MIA690 loaded onto the GMO-MEN carrier at physiological pH. This result is consistent with the binding capacity of chemotherapeutic drugs to MENs previously reported [11] . An important challenge in the administration of GHRH antagonists is their short half-life [25] . Various nanocarriers are emerging as delivery systems to improve half-life of therapeutic peptides [45] . The binding force between MIA690 and MENs at physiological pH indicates that GHRH antagonists may avoid early degradation when loaded onto MEN carriers in order to reach target sites. Thompson et al. have shown that iron oxide nanoparticles can be dragged across an in vitro BBB through the application of a magnetic field gradient. Furthermore, recent studies have shown that manganese ferric oxide particles coated with serum albumin can cross in vivo BBB in mice through adsorptive transcytosis and through the gap junctions. Since MENs possess similar properties, we can expect their transport across BBB through similar mechanisms with an added advantage of no thermal damage associated with conventional iron oxide nanoparticles. It is worth noting that MEN-based delivery and release of peptides across BBB is independent of the biochemical microenvironment; in contrast, it is mostly determined by externally controlled d.c. and a.c. magnetic fields. Thus, a logical approach to MEN-based drug delivery is adjusting magnetic field gradients in sequence to penetrate the BBB with a stronger magnetic field gradient, and subsequently target glioblastoma with a weaker magnetic field [46, 47] . As a primary aim, we investigated the efficacy of MENs as a drug delivery system for the GHRH antagonist MIA690 to glioblastoma cells. We used U-87MG human glioblastoma malignant cells, which express the primary functional receptor responsible for mediating the effects of GHRH and GHRH antagonists in tumors [19, 26] . Our results indicate that MENs loaded with MIA690 provided greater intracellular uptake compared with MIA690 treatment alone. Within a 24-h period, the percentage of MEN-mediated drug penetration was 6.9-times greater after a 12-h d.c. field exposure than after MIA690 treatment alone (p < 0.01). Penetration mediated by MENs was further enhanced with the subsequent application of an a.c. magnetic field, which increased an intracellular MIA690 uptake by a factor of 1.6 compared with 12-h d.c. treatment alone and 11-times compared with traditional free MIA690 treatment (p < 0.05 and p < 0.01, respectively). Our results show a significant relationship between MIA690 uptake and cell inhibition, and although the intracellular levels of MIA690 were not significant in cell lysate collected 48 h post-treatment, it may be a consequence of efflux of the GHRH antagonist, which is able to bind with high affinity to the GHRH membrane receptor and lead to an increase in cell death at 48 h. Taken together, the effect of MIA690 uptake at 24 h may be associated with a decline in U-87MG cell proliferation at future science group www.futuremedicine.com 48 h post-treatment. To our knowledge, this is the first paper to demonstrate an intracellular drug delivery of a GHRH antagonist to glioblastoma cells and its effectiveness in enhancing inhibition of glioblastoma cells in vitro compared with traditional MIA690 treatment. Intracellular delivery of GHRH antagonists offers a novel modality to the existing GHRH treatments. Currently, the mechanism action of GHRH antagonists involves binding to external pituitary receptors to reduce secretion of GH that inhibits the release of IGF-I associated with tumorigenic effects in vivo, as well as its binding to GHRH receptors of local autocrine/paracrine tumor cells followed by internalization and increased tumorigenicity both in vivo and in vitro [17, 24, 48] . We demonstrated that MIA690-GMO-MENs wirelessly coupled to externally controlled magnetic fields increased intracellular levels of GHRH antagonist MIA690 in U-87MG glioblastoma cells. Furthermore, cell inhibition was significantly associated with the uptake of MIA690 ( Figure 4B ). These results imply that MEN-mediated uptake of MIA690 provides a potential intracellular GHRH antagonist pool to compete with endogenous tumorigenic GHRH. Conventional magnetic nanoparticles exploit a.c. fields often at relatively high frequencies (∼>100 kHz) to heat tumor sites causing hyperthermic cell death [49, 50] . Such high-frequency hypothermia-based therapies are prone to side effects because of the difficulty to control thermal effects. Alternatively, based on their new physical high-specificity targeting mechanism, MENs exhibit high-efficacy ME coupling that enables responsiveness to substantially lower frequency a.c. fields [11] . To ensure that MENs exposed to a.c. fields indeed did not contribute to cell death due to unintended hyperthermia, temperatures were measured on the surface of U-87MG cells across treatment groups using an IR camera ( Figure 5A ). As expected at such low frequencies and consistent with our previous studies, only negligible heat dissipation was observed [11] . We further investigated the effect of time of exposure to a low-frequency (50 Hz) a.c. field coupled to MENs on U-87MG cell viability. The results showed that even the longest (2 h) exposure barely affected cell viability ( Figure 5B ). It is important to note that a relatively new technology utilizing external a.c. electric fields is being developed to target gliomas. The technology known as tumor-treating field (TTF) interrupts cell growth of rapidly dividing tumor cells during stages of mitosis, leading to blebbing and resulting in cell death [51, 52] .
However, the TTF approach works in a relatively high-frequency range (100-500 kHz) and displays a relatively low specificity [53, 54] . For comparison, MEN-based drug delivery utilizes a.c. frequencies in the near d.c. range, which are three orders of magnitude smaller than those in the TTF frequency range. Therefore, it is likely that the antitumorigenic effects in this study are due an intracellular drug uptake and not due to a direct disruption of mitosis. Taken together, these data indicate that MEN-mediated drug delivery may increase intracellular levels of MIA690 at 24 h and is associated with lower U-87MG cell viability at 48 h post-treatment. Highest MEN-mediated drug penetration was achieved when MIA-690-GMO-MENs were exposed to 100 Oe for 12 h + 50 Hz for 2 h. It is worth mentioning that future research into MEN-targeted drug delivery in combination with localizing TTF therapy to treat gliomas is warranted.
Conclusion
Overall, this study reports major improvements in therapy of human glioblastoma with a GHRH antagonist. Taking advantage of the unique properties of MENs, these results suggest that GMO-MENs effectively bind MIA690, provide controlled intracellular drug delivery and specifically target human glioblastoma cells.
Future perspective
MENs promise to solve the important challenge in the treatment of gliomas through the penetration of the intact BBB for directed therapeutic delivery [10, 55, 56] . Previously, it has been shown that drug-loaded MENs can penetrate the BBB and release the drug deep in the brain on demand. The current data indicate that MENs specifically penetrate human glioblastoma cells while sparing nonmalignant HBMECs. The implications of high-specificity MEN drug delivery to human glioblastoma cells are twofold: the potential to improve intracellular drug uptake in human glioblastomas, and avoiding intracellular accumulation in HBMECs. Certain nanoparticles may experience diminished transport across the BBB due to intracellular accumulation of large aggregates within the endothelial cells [57] . Conversely, MENs may overcome this type of accumulation in endothelial cells using a relatively weak d.c. magnetic field gradient to 'pull' them across the BBB into parenchymal tissues. As a final remark, it is noteworthy that, in general, this nanotechnology could be applied to treat not only brain tumors but also neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. No writing assistance was utilized in the production of this manuscript.
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